Skip to main content

Table 11 Other reported adverse events

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

Condition

Observations

Treatment

Hypertension

1

UP446 250 mg

Varicose veins

1

UP446 250 mg

Fluid in knee

1

UP446 250 mg

Reduced flexibility

1

Placebo

Psoriasis

2

UP446 250 and 500 mg